Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Net Cash Flow (2016 - 2025)

Conmed's Net Cash Flow history spans 16 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 115.75% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $13.9 million, up 382.42%, while the annual FY2025 figure was $13.9 million, 382.42% up from the prior year.
  • Net Cash Flow reached $1.9 million in Q4 2025 per CNMD's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $29.6 million in Q2 2022 to a low of -$18.5 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $793650.0, with a median of $1.6 million recorded in 2023.
  • The largest YoY upside for Net Cash Flow was 4875.58% in 2021 against a maximum downside of 2238.06% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$10.2 million in 2021, then skyrocketed by 37.2% to -$6.4 million in 2022, then dropped by 12.89% to -$7.2 million in 2023, then crashed by 62.91% to -$11.8 million in 2024, then soared by 115.75% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Net Cash Flow are $1.9 million (Q4 2025), $5.0 million (Q3 2025), and -$3.1 million (Q2 2025).